FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2615961540> ?p ?o ?g. }

• W2615961540 abstract "Abstract Background. Neutropenia is a common toxicity in patients (pts) with lymphoma (lymph) who receive myeloablative chemotherapy (CT). It frequently leads to CT delays and dose reductions, potentially compromising the clinical outcome. Granulocyte colonystimulating factors (G-CSFs) represented a major development in the prevention of this disorder. Current European and US guidelines (2006) recommend primary prophylaxis with G-CSF for patients at overall ≥20% risk of febrile neutropenia (FN) due to CT and patient-related factors. Methods. A multicentre, prospective, observational study, in adult pts with lymph initiating a new CT regimen with at least 4 planned cycles, assessing the incidence of grade 3–4 neutropenia (G3–4N) [defined as absolute neutrophil count &lt;1.0 × 109/L] over the first four cycles of CT regimens with high or intermediate FN risk (FN risk ≥20% or 10–20%, respectively). Results. This interim analysis contains data from 270 consecutive lymph pts (300 pts per protocol) from 31 Spanish centres from November 2005 to November 2007. Pts were 53.3% male, median age 57.5 years (range: 19–85), 87.0% ECOG 0-1 and 60.9% III–IV stage (43.6% IV stage). 71.8% of lymph pts were treated with CHOP-based CT (83.0% R-CHOP). G-CSF was used in 83.9% of pts (76.8% primary prophylaxis (PP), 23.2% secondary prophylaxis (SP)). The G-CSF received was 49.1% filgrastim and 50.9% pegfilgrastim. Global incidence of G3-4N over the first four cycles was 39.9%. The G3-4N incidence was 39.6% in pts treated with pegfilgrastim while it was 52.3% in pts treated with filgrastim. Pts treated with PP had an FN incidence of 15.4% while the incidence was 22.0% in those receiving SP. Full dose on schedule (FDOS) [defined as ≤ 15% dose reduction and ≤ 3 days dose delay] was achieved in 65.1% of pts treated as PP and 60.8% of pts treated as SP. Conclusion. This study of clinical practice suggests that current guideline recommendations on the use of G-CSF PP with CT are becoming widely adopted in Spain. In patients receiving CT with intermediate/high FN risk, G-CSF PP and pegfilgrastim prophylaxis seemed to reduce neutropenia events compared with SP and Filgrastim. PP also improved the delivery of CT at full dose on schedule." @default.
• W2615961540 created "2017-05-26" @default.
• W2615961540 creator A5010206363 @default.
• W2615961540 creator A5020072435 @default.
• W2615961540 creator A5021648970 @default.
• W2615961540 creator A5051368099 @default.
• W2615961540 creator A5069417979 @default.
• W2615961540 creator A5073093146 @default.
• W2615961540 creator A5078340362 @default.
• W2615961540 creator A5086848835 @default.
• W2615961540 creator A5087080626 @default.
• W2615961540 creator A5087171473 @default.
• W2615961540 date "2008-11-16" @default.
• W2615961540 modified "2023-09-27" @default.
• W2615961540 title "A Prospective, Observational Study on the Incidence of Chemotherapy-Induced Neutropenia in Lymphoma Patients" @default.
• W2615961540 doi "https://doi.org/10.1182/blood.v112.11.4955.4955" @default.
• W2615961540 hasPublicationYear "2008" @default.
• W2615961540 type Work @default.
• W2615961540 sameAs 2615961540 @default.
• W2615961540 citedByCount "0" @default.
• W2615961540 crossrefType "journal-article" @default.
• W2615961540 hasAuthorship W2615961540A5010206363 @default.
• W2615961540 hasAuthorship W2615961540A5020072435 @default.
• W2615961540 hasAuthorship W2615961540A5021648970 @default.
• W2615961540 hasAuthorship W2615961540A5051368099 @default.
• W2615961540 hasAuthorship W2615961540A5069417979 @default.
• W2615961540 hasAuthorship W2615961540A5073093146 @default.
• W2615961540 hasAuthorship W2615961540A5078340362 @default.
• W2615961540 hasAuthorship W2615961540A5086848835 @default.
• W2615961540 hasAuthorship W2615961540A5087080626 @default.
• W2615961540 hasAuthorship W2615961540A5087171473 @default.
• W2615961540 hasConcept C120665830 @default.
• W2615961540 hasConcept C121332964 @default.
• W2615961540 hasConcept C126322002 @default.
• W2615961540 hasConcept C141071460 @default.
• W2615961540 hasConcept C2776694085 @default.
• W2615961540 hasConcept C2777063308 @default.
• W2615961540 hasConcept C2777767877 @default.
• W2615961540 hasConcept C2778336483 @default.
• W2615961540 hasConcept C2778658803 @default.
• W2615961540 hasConcept C2778850193 @default.
• W2615961540 hasConcept C2779171977 @default.
• W2615961540 hasConcept C2781413609 @default.
• W2615961540 hasConcept C61511704 @default.
• W2615961540 hasConcept C71924100 @default.
• W2615961540 hasConcept C74133956 @default.
• W2615961540 hasConcept C90924648 @default.
• W2615961540 hasConceptScore W2615961540C120665830 @default.
• W2615961540 hasConceptScore W2615961540C121332964 @default.
• W2615961540 hasConceptScore W2615961540C126322002 @default.
• W2615961540 hasConceptScore W2615961540C141071460 @default.
• W2615961540 hasConceptScore W2615961540C2776694085 @default.
• W2615961540 hasConceptScore W2615961540C2777063308 @default.
• W2615961540 hasConceptScore W2615961540C2777767877 @default.
• W2615961540 hasConceptScore W2615961540C2778336483 @default.
• W2615961540 hasConceptScore W2615961540C2778658803 @default.
• W2615961540 hasConceptScore W2615961540C2778850193 @default.
• W2615961540 hasConceptScore W2615961540C2779171977 @default.
• W2615961540 hasConceptScore W2615961540C2781413609 @default.
• W2615961540 hasConceptScore W2615961540C61511704 @default.
• W2615961540 hasConceptScore W2615961540C71924100 @default.
• W2615961540 hasConceptScore W2615961540C74133956 @default.
• W2615961540 hasConceptScore W2615961540C90924648 @default.
• W2615961540 hasLocation W26159615401 @default.
• W2615961540 hasOpenAccess W2615961540 @default.
• W2615961540 hasPrimaryLocation W26159615401 @default.
• W2615961540 hasRelatedWork W1645808469 @default.
• W2615961540 hasRelatedWork W2008078749 @default.
• W2615961540 hasRelatedWork W2018503914 @default.
• W2615961540 hasRelatedWork W2223222177 @default.
• W2615961540 hasRelatedWork W2242901026 @default.
• W2615961540 hasRelatedWork W2315326483 @default.
• W2615961540 hasRelatedWork W2559481507 @default.
• W2615961540 hasRelatedWork W2562736839 @default.
• W2615961540 hasRelatedWork W2575900396 @default.
• W2615961540 hasRelatedWork W2586508828 @default.
• W2615961540 hasRelatedWork W2586600246 @default.
• W2615961540 hasRelatedWork W2587049799 @default.
• W2615961540 hasRelatedWork W2589914765 @default.
• W2615961540 hasRelatedWork W2591509707 @default.
• W2615961540 hasRelatedWork W2795003048 @default.
• W2615961540 hasRelatedWork W2944553536 @default.
• W2615961540 hasRelatedWork W2945925135 @default.
• W2615961540 hasRelatedWork W2999466298 @default.
• W2615961540 hasRelatedWork W2999558581 @default.
• W2615961540 hasRelatedWork W3141831760 @default.
• W2615961540 isParatext "false" @default.
• W2615961540 isRetracted "false" @default.
• W2615961540 magId "2615961540" @default.
• W2615961540 workType "article" @default.